Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 28, 2012, Pages 11294-11299

  Sengupta, Poulomi ^a,b   Basu, Sudipta ^a,b,h   Soni, Shivani ^a,b,i   Pandey, Ambarish ^a,b   Roy, Bhaskar ^a,b   Oh, Michael S ^a,b   Chin, Kenneth T ^a   Paraskar, Abhimanyu S ^a,b   Sarangi, Sasmit ^a,b   Connor, Yamicia ^a,b,c   Sabbisetti, Venkata S ^a,b   Kopparam, Jawahar ^a,b   Kulkarni, Ashish ^a,b   Muto, Katherine ^a   Amarasiriwardena, Chitra ^a,d   Jayawardene, Innocent ^a,d   Lupoli, Nicola ^a,d   Dinulescu, Daniela M ^a,b   Bonventre, Joseph V ^a,b   Mashelkar, Raghunath A ^a,e   Sengupta, Shiladitya ^a,b,c,f,g   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL CHEMICAL LABORATORY   (India)

^f Indo United States Joint Center for Nanobiotechnology   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

ⁱ ALABAMA STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Nanomedicine

Indexed keywords

CARBOPLATIN; CHOLESTEROL; CISPLATIN; MACROGOL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MOUSE; NANOCHEMISTRY; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; CISPLATIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; INHIBITORY CONCENTRATION 50; KIDNEY; MICE; MODELS, CHEMICAL; NANOPARTICLES; NANOTECHNOLOGY; PLATINUM; SUCCINIC ACID;

MURINAE;

EID: 84863908485     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203129109     Document Type: Article

References (39)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907.
2. World Health Organization (2008) WHO Cancer Report. Available at http://www.who.int/cancer/en/. Accessed June 12, 2012.
3. Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 5:161-171.
4. Yuan F, et al. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356. (Pubitemid 24225946)
5. Northfelt DW, et al. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63. (Pubitemid 26058811)
6. Desai N, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324. (Pubitemid 43342524)
7. Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13:248-260.
8. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
9. Avgoustakis K, et al. (2002) PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79:123-135. (Pubitemid 34164166)
10. Haxton KJ, Burt HM (2009) Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci 98:2299-2316.
11. Zamboni WC, et al. (2004) Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329-336. (Pubitemid 38392358)
12. White SC, et al. (2006) Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 95:822-828. (Pubitemid 44498096)
13. Choi HS, et al. (2007) Renal clearance of quantum dots. Nat Biotechnol 25:1165-1170.
14. Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307-314. (Pubitemid 9003377)
15. Davies MS, Berners-Price SJ, Hambley TW (2000) Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA. Inorg Chem 39:5603-5613. (Pubitemid 32065704)
16. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979. (Pubitemid 16080411)
17. Los G, et al. (1991) Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 42:357-363.
18. Paraskar A, et al. (2011) Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology 22:265101.
19. Paraskar AS, et al. (2010) Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci USA 107:12435-12440.
20. Sengupta S, et al. (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436:568-572. (Pubitemid 41112931)
21. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM (1995) Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: Cross-resistance and protein changes. Br J Cancer 71:676-683.
22. Sato N, et al. (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60:7052-7056. (Pubitemid 32059184)
23. Cuatrecasas M, et al. (1998) K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 82:1088-1095. (Pubitemid 28136522)
24. Dinulescu DM, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63-70. (Pubitemid 40215839)
25. Lehn JM (1995) Supramolecular Chemistry: Concepts and Perspectives (VCH, New York).
26. Lehn JM (2002) Toward complex matter: Supramolecular chemistry and self-organization. Proc Natl Acad Sci USA 99:4763-4768.
27. Chen KJ, et al. (2011) A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials 32:2160-2165.
28. Chen KJ, et al. (2012) The therapeutic efficacy of camptothecin- encapsulated supramolecular nanoparticles. Biomaterials 33:1162-1169.
29. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: A review. Am J Med Sci 334:115-124. (Pubitemid 47262919)
30. Bedu-Addo FK, Tang P, Xu Y, Huang L (1996) Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: Sterically stabilized liposome formulations. Pharm Res 13:718-724. (Pubitemid 26156220)
31. Matsumori N, et al. (2004) An amphotericin B-ergosterol covalent conjugate with powerful membrane permeabilizing activity. Chem Biol 11:673-679. (Pubitemid 38708836)
32. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
33. Mosqueira VC, et al. (2001) Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967-2979. (Pubitemid 32768704)
34. Vaidya VS, et al. (2010) Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28:478-485.
35. Rademaker-Lakhai JM, et al. (2004) A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10:3386-3395. (Pubitemid 38685444)
36. Lin X, et al. (2004) Improved targeting of platinum chemotherapeutics. the anti-tumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer 40:291-297. (Pubitemid 38077033)
37. Sugano K, et al. (2010) Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9:597-614.
38. Vercauteren D, et al. (2010) The use of inhibitors to study endocytic pathways of gene carriers: Optimization and pitfalls. Mol Ther 18:561-569.
39. Jian W, Levitt JM, Lerner SP, Sonpavde G (2009) Preclinical antitumor and anti-angiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinoma (TCC). J Clin Oncol 27:e16018.